Status:
COMPLETED
Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity
Lead Sponsor:
Chonbuk National University Hospital
Conditions:
Immunity
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
The investigators performed randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Cordyceps sinensis mycelium culture extract (Paecilomyces hepiali, CBG-CS-2)...
Eligibility Criteria
Inclusion
- Males and females 20-80 years old
- Who had suffered more than twice Upper respiratory infection\* disorder or common cold causing URI
- Able to give informed consent
Exclusion
- WBC concentration below 3000 ㎕
- Subjects vaccinated against influenza within the last 6 months prior to the study
- Subjects with Upper respiratory infection at screening visit
- Subjects with BMI \< 18.5 kg/m2 at screening visit
- Allergic or hypersensitive to any of the ingredients in the test products
- Diagnosed of gastrointestinal disease such as Immune-related diseases, severe hepatic, renal failure, and diabetes
- History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery
- History of alcohol or substance abuse
- Participation in any other clinical trials within past 2 months
- Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
- Pregnant or lactating women etc.
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT02244372
Start Date
September 1 2014
End Date
February 1 2015
Last Update
August 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Trial Center for Functional Foods; Chonbuk National University Hospital
Jeonju, Jeollabuk-do, South Korea, 560-822